Ascendis Pharma A (ASND) Receivables - Other (2016 - 2025)

Ascendis Pharma A has disclosed Receivables - Other across 10 years of filings, most recently posting $17.0 million for Q4 2025.

• Receivables - Other for Q4 2025 came in at $17.0 million, up 69.25% year-over-year; the trailing twelve-month figure through Dec 2025 was $17.0 million (up 69.25% YoY), and the FY2025 annual result was $17.0 million, up 69.25% from the prior year.
• Receivables - Other came in at $17.0 million for Q4 2025 at Ascendis Pharma A, up from $10.0 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $23.0 million in Q4 2021 to a low of $10.0 million in Q4 2024.
• The 5-year median for Receivables - Other is $17.0 million (2025), against an average of $16.7 million.
• Across the five-year window, Receivables - Other soared 10377.56% in 2021 and slumped 51.19% in 2024, its largest moves.
• Ascendis Pharma A's Receivables - Other stood at $23.0 million in 2021, then slumped by 43.04% to $13.1 million in 2022, then jumped by 56.93% to $20.5 million in 2023, then plunged by 51.19% to $10.0 million in 2024, then surged by 69.25% to $17.0 million in 2025.
• The last three Receivables - Other figures came in at $17.0 million (Q4 2025), $10.0 million (Q4 2024), and $20.5 million (Q4 2023), per Business Quant data.